Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBITDA Margin (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed EBITDA Margin for 14 consecutive years, with 60.45% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 7837.0% year-over-year to 60.45%, compared with a TTM value of 109.08% through Dec 2025, up 5663.0%, and an annual FY2025 reading of 130.65%, up 4927.0% over the prior year.
  • EBITDA Margin was 60.45% for Q4 2025 at Enanta Pharmaceuticals, up from 121.56% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 60.45% in Q4 2025 and bottomed at 221.7% in Q1 2023.
  • Average EBITDA Margin over 5 years is 152.93%, with a median of 152.03% recorded in 2021.
  • The sharpest move saw EBITDA Margin tumbled -10453bps in 2021, then surged 8282bps in 2025.
  • Year by year, EBITDA Margin stood at 109.99% in 2021, then dropped by -16bps to 127.25% in 2022, then tumbled by -52bps to 193.78% in 2023, then increased by 28bps to 138.82% in 2024, then soared by 56bps to 60.45% in 2025.
  • Business Quant data shows EBITDA Margin for ENTA at 60.45% in Q4 2025, 121.56% in Q3 2025, and 103.16% in Q2 2025.